Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Mersana Therapeutics revenue
Mersana Therapeutics's revenue is $40.5 million.
What is Mersana Therapeutics's revenue?
- Mersana Therapeutics's revenue growth from 2016 to 2024 is 60.89%.
- Mersana Therapeutics has 169 employees, and the revenue per employee ratio is $239,627.
- Mersana Therapeutics's peak quarterly revenue was $41.0M in 2019(q1).
- Mersana Therapeutics peak revenue was $42.1M in 2019.
- Mersana Therapeutics annual revenue for 2024 was 40.5M, 9.88% growth from 2023.
- Mersana Therapeutics annual revenue for 2023 was 36.9M, 38.65% growth from 2022.
On this page
Zippi applies for you, and finds you a job.
Mersana Therapeutics historical revenue
Mersana Therapeutics's peak revenue was $42.1M in 2019. The peak quarterly revenue was $41.0M in 2019(q1).
Mersana Therapeutics's revenue increased from $25.2m in 2016 to $40.5M currently. That's a 60.89% change in annual revenue.
Mersana Therapeutics annual revenue
Mersana Therapeutics annual revenue over time
| Fiscal year / year | Mersana Therapeutics revenue |
|---|---|
| 2016 | $25.2M |
| 2017 | $17.5M |
| 2018 | $10.6M |
| 2019 | $42.1M |
| 2020 | $828,000 |
| 2021 | $43,000 |
| 2022 | $26.6M |
| 2023 | $36.9M |
| 2024 | $40.5M |
How accurately did Mersana Therapeutics' revenue projections match actual performance?
Mersana Therapeutics annual growth
Mersana Therapeutics saw the greatest revenue growth in 2022, when revenue increased by 61,716.28%.
Mersana Therapeutics had the lowest revenue growth in 2020, when revenue changed by -98.03%.
Mersana Therapeutics annual growth rate over time
| Year | Mersana Therapeutics growth |
|---|---|
| 2017 | -30%↓ |
| 2018 | -40%↓ |
| 2019 | 298%↑ |
| 2020 | -98%↓ |
| 2021 | -95%↓ |
| 2022 | 61716%↑ |
| 2023 | 39%↑ |
| 2024 | 10%↑ |
Mersana Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Mersana Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | - | $3.7M | $6.3M | $3.3M |
| 2018 | $3.1M | $4.2M | $2.2M | $1.2M |
| 2019 | $41.0M | $202,000 | $844,000 | $42,000 |
| 2020 | $11,000 | $796,000 | $11,000 | $11,000 |
| 2021 | $11,000 | $11,000 | $11,000 | $11,000 |
| 2022 | $2.0M | $4.3M | $5.6M | $14.7M |
| 2023 | $7.8M | $10.7M | $7.7M | $10.7M |
| 2024 | $9.2M | $2.3M | $12.6M | $16.4M |
Mersana Therapeutics jobs nearby
Do you work at Mersana Therapeutics?
Is Mersana Therapeutics transparent about its revenue structure?
Mersana Therapeutics financial information
| CEO | Anna Protopapas |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 169 |
| Date Founded | 2001 |
| Headquarters | Cambridge, Massachusetts |
| Number of Locations | 1 |
| Revenue | $40.5M |
| Net Income | -$204,212,000 |
| Tax Rate | -0.0% |
| Total Assets | $334,340,000 |
| Ticker | MRSN |
Mersana Therapeutics jobs you might like
Mersana Therapeutics financing
Mersana Therapeutics received early financing of $21.0M on 2005-11-08.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $21M | 11/2005 |
| Debt Financing | $2.5M | 02/2010 |
| Debt Financing | $10M | 04/2012 |
| Series A | $27M | 07/2012 |
| Series A | $14.5M | 04/2014 |
| Series B | $35M | 03/2015 |
| Series C | $33M | 06/2016 |
| Post Ipo Equity | $97.8M | 02/2019 |
| Post Ipo Equity | $65M | 04/2020 |
| Post Ipo Equity | $174.8M | 05/2020 |
Mersana Therapeutics investors
| Investors | Security type |
|---|---|
| Eight Roads Ventures | Series Unknown |
| ProQuest Investments | Series Unknown |
| Lansing Brown Investments | Series Unknown |
| Rho Ventures | Series Unknown |
| PureTech Health | Series Unknown |
| F Prime Capital | Series Unknown |
| Cape Family Fund | Series Unknown |
| 180 Degree Capital Corp. | Series Unknown |
| Harris and Harris Group | Series A |
| Rho Ventures | Series A |
| New Enterprise Associates (NEA) | Series A |
| ProQuest Investments | Series A |
| Pfizer Venture Investments | Series A |
| F Prime Capital | Series A |
| New Enterprise Associates (NEA) | Series A |
| F Prime Capital | Series A |
| New Enterprise Associates (NEA) | Series B |
| Pfizer Venture Investments | Series B |
| F Prime Capital | Series B |
| Rock Springs Capital | Series B |
| Elliott Sigal | Series B |
| Takeda Pharmaceutical | Series C |
| New Enterprise Associates (NEA) | Series C |
| Wellington Management | Series C |
| Cormorant Asset Management | Series C |
| ArrowMark Partners | Series C |
| Rock Springs Capital | Series C |
| Consonance Capital | Post Ipo Equity |
| Bain Capital Life Sciences | Post Ipo Equity |
| AVORO CAPITAL ADVISORS LLC | Post Ipo Equity |
Mersana Therapeutics competitors
Mersana Therapeutics's top competitor, Seagen, earned an annual revenue of $2.0B.
Mersana Therapeutics's smallest competitor is Sirnaomics with revenue of $7.5M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Seagen | - | $2.0B | 900 | - |
| Epizyme | - | $37.4M | 124 | - |
| Sesen Bio | - | $19.6M | 35 | - |
| Bolt Biotherapeutics | - | $7.7M | 91 | - |
| ImmunoGen | - | $108.8M | 75 | - |
| G1 Therapeutics | - | $82.5M | 148 | - |
| bluebird bio | - | $3.7M | 518 | - |
| Genocea | - | - | 59 | - |
| Moderna | - | $3.2B | 2,500 | - |
| Sirnaomics | - | $7.5M | 300 | - |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Mersana Therapeutics highest paying jobs
Zippia gives an in-depth look into the details of Mersana Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Mersana Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Mersana Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Mersana Therapeutics. The data presented on this page does not represent the view of Mersana Therapeutics and its employees or that of Zippia.
Mersana Therapeutics may also be known as or be related to MERSANA THERAPEUTICS INC., Mersana Therapeutics, Mersana Therapeutics Inc and Mersana Therapeutics, Inc.